ArticleFrontiers in oncology2019
Genomic Profiles of a Patient of Pulmonary Hepatoid Adenocarcinoma With High AFP Level: A Case Report.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Hepatoid adenocarcinoma of the lung with normal serum alpha-fetoprotein managed with thoracic radiotherapy followed by tislelizumab plus lenvatinib: a case report and systematic review.Frontiers in oncology · 2026Pooled it
- Optimal treatment strategies for hepatoid adenocarcinoma of the lung: insights from a comprehensive analysis.BMC cancer · 2024Pooled it
- Hepatoid Adenocarcinoma of the Lung: A Systematic Review of the Literature From 1981 to 2020.Frontiers in oncology · 2021Pooled it
- Hepatoid adenocarcinoma of the lung: clinicopathologic and molecular analysis of 17 cases.Virchows Archiv : an international journal of pathology · 2026Article
- Long term survival of advanced hepatoid adenocarcinoma of lung secondary to idiopathic pulmonary fibrosis: a case report.Frontiers in oncology · 2025Article
- Primary hepatoid adenocarcinoma of the lung in patient with silicosis: a case report and literature review.Frontiers in oncology · 2024Article
- Hepatoid Adenocarcinoma of the Lung: A Review of the Most Updated Literature and a Presentation of Three Cases.Journal of clinical medicine · 2023Article
- A case report of pulmonary hepatoid adenocarcinoma: promoting standardized diagnosis and treatment of the rare disease.Frontiers in immunology · 2023Article
- Whole-exome sequencing and bioinformatics analysis of a case of non-alpha-fetoprotein-elevated lung hepatoid adenocarcinoma.Frontiers in pharmacology · 2022Article
- Primary Hepatoid Adenocarcinoma of the Lung: A Systematic Literature Review.OncoTargets and therapy · 2022Article
- Merged hepatopulmonary features in hepatoid adenocarcinoma of the lung: a systematic review.American journal of translational research · 2021Review
- Radiotherapy of Pulmonary Hepatoid Adenocarcinoma with Intrahepatic Hemangioma: A Case Report.OncoTargets and therapy · 2020Article
- Hepatoid Adenocarcinoma of the Lung.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoid adenocarcinoma of lung (HAL) is a rare and aggressive tumor. The current study reported a new HAL case in the right lower lung with high serum α-fetoprotein (AFP) level in a 71-year-old male patient. After the confirmation of morphology and immunohistochemistry, the patient was diagnosed clinically with HAL and treated with radio-frequency ablation. However, the patient whose disease progressed eventually died 4 months after diagnosis. Whole genome sequencing analysis identified a driver gene mutation in the FAT atypical cadherin 1 gene (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.